Agree. Having traded a few of these, I see usual

Agree. Having traded a few of these, I see usually a pop in sp that returns back to normal. I still can’t believe ptn with a similar setup, something like 300M milestones at 10% cut dropped after fda approval. Does not seem to be usually good for the company that sold. The ones I see usually have other drugs in the pipeline the cash will be used for.

Anyone have an example of licensing a drug for just one indication? I’m not sure that would work. Maybe BP would want the entire enchilada for the entire region.

A doctor diagnoses a patient and prescribes leronlimab. The patient takes the prescription to a pharmacy to fill. How does the BP partner know what the patient was diagnosed with to separate revenue? Does the doctor always give diagnoses on the script? Right now I thought just narcotics must have them, but not my area. Will the pharmacy share the info with BP? Or will the insurance company? What if the patient had both HIV and cancer? What if neither. Seems like a logistical nightmare.